[1] Siegel, R.L., Miller, K.D. and Jemal, A. (2015) Cancer Statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5-29.
http://dx.doi.org/10.3322/caac.21254
[2] Siegel, R., Naishadham, D. and Jemal, A. (2013) Cancer Statistics, 2013. CA: A Cancer Journal for Clinicians, 63, 11- 30.
http://dx.doi.org/10.3322/caac.21166
[3] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90.
http://dx.doi.org/10.3322/caac.20107
[4] Paulson, A.S., Tran Cao, H.S., Tempero, M.A. and Lowy, A.M. (2013) Therapeutic Advances in Pancreatic Cancer. Gastroenterology, 144, 1316-1326.
http://dx.doi.org/10.1053/j.gastro.2013.01.078
[5] Michl, P. and Gress, T.M. (2013) Current Concepts and Novel Targets in Advanced Pancreatic Cancer. Gut, 62, 317-326.
http://dx.doi.org/10.1136/gutjnl-2012-303588
[6] Burris 3rd, H.A., Moore, M.J., Andersen, J., et al. (1997) Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 15, 2403-2413.
[7] Kothari, N., Saif, M.W. and Kim, R. (2013) First-Line Treatment for Advanced Pancreatic Cancer. JOP: Journal of the Pancreas, 14, 129-132.
[8] Long, J., Zhang, Y., Yu, X., et al. (2011) Overcoming Drug Resistance in Pancreatic Cancer. Expert Opinion on Therapeutic Targets, 15, 817-828.
http://dx.doi.org/10.1517/14728222.2011.566216
[9] Arumugam, T., Ramachandran, V., Fournier, K.F., et al. (2009) Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer. Cancer Research, 69, 5820-5828.
http://dx.doi.org/10.1158/0008-5472.CAN-08-2819
[10] Wu, Q., Miele, L., Sarkar, F.H. and Wang, Z. (2012) The Role of EMT in Pancreatic Cancer Progression. Pancreatic Disorders & Therapy, 2.
http://dx.doi.org/10.4172/2165-7092.1000e121
[11] Sarkar, F.H., Li, Y., Wang, Z. and Kong, D. (2009) Pancreatic Cancer Stem Cells and EMT in Drug Resistance and Metastasis. Minerva Chirurgica, 64, 489-500.
[12] Hermann, P.C., Huber, S.L., Herrler, T., et al. (2007) Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer. Cell Stem Cell, 1, 313-323.
http://dx.doi.org/10.1016/j.stem.2007.06.002
[13] Hage, C., Rausch, V., Giese, N., et al. (2013) The Novel C-Met Inhibitor Cabozantinib Overcomes Gemcitabine Resistance and Stem Cell Signaling in Pancreatic Cancer. Cell Death & Disease, 4, e627.
http://dx.doi.org/10.1038/cddis.2013.158
[14] Vaz, A.P., Ponnusamy, M.P., Rachagani, S., Dey, P., Ganti, A.K. and Batra, S.K. (2014) Novel Role of Pancreatic Differentiation 2 in Facilitating Self-Renewal and Drug Resistance of Pancreatic Cancer Stem Cells. British Journal of Cancer, 111, 486-496.
[15] Hong, S.P., Wen, J., Bang, S., Park, S. and Song, S.Y. (2009) CD44-Positive Cells Are Responsible for Gemcitabine Resistance in Pancreatic Cancer Cells. International Journal of Cancer, 125, 2323-2331.
[16] Ischenko, I., Seeliger, H., Jauch, K.W. and Bruns, C.J. (2009) Metastatic Activity and Chemotherapy Resistance in Human Pancreatic Cancer—Influence of Cancer Stem Cells. Surgery, 146, 430-434.
http://dx.doi.org/10.1016/j.surg.2009.05.003
[17] Li, C., Lee, C.J. and Simeone, D.M. (2009) Identification of Human Pancreatic Cancer Stem Cells. Methods in Molecular Biology, 568, 161-173.
http://dx.doi.org/10.1007/978-1-59745-280-9_10
[18] Niess, H., Camaj, P., Renner, A., et al. (2014) Side Population Cells of Pancreatic Cancer Show Characteristics of Cancer Stem Cells Responsible for Resistance and Metastasis. Targeted Oncology, 10, 215-227.
[19] Hung, S.W., Mody, H.R. and Govindarajan, R. (2012) Overcoming Nucleoside Analog Chemoresistance of Pancreatic Cancer: A Therapeutic Challenge. Cancer Letters, 320, 138-149.
http://dx.doi.org/10.1016/j.canlet.2012.03.007
[20] Shah, A.N., Summy, J.M., Zhang, J., Park, S.I., Parikh, N.U. and Gallick, G.E. (2007) Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells. Annals of Surgical Oncology, 14, 3629-3637.
http://dx.doi.org/10.1245/s10434-007-9583-5
[21] Yan, X.D., Li, M., Yuan, Y., Mao, N. and Pan, L.Y. (2007) Biological Comparison of Ovarian Cancer Resistant Cell Lines to Cisplatin and Taxol by Two Different Administrations. Oncology Reports, 17, 1163-1169.
http://dx.doi.org/10.3892/or.17.5.1163
[22] Castellanos, J.A., Merchant, N.B. and Nagathihalli, N.S. (2013) Emerging Targets in Pancreatic Cancer: Epithelial- Mesenchymal Transition and Cancer Stem Cells. OncoTargets and Therapy, 6, 1261-1267.